Dolnoslaskie Centrum Onkologii Pulmonologii I Hematologii — Clinical Trial Site

81 Registered trials

35 Currently recruiting

Organisation

Dolnoslaskie Centrum Onkologii Pulmonologii I Hematologii

Location

Wroclaw, Poland

Identifier

ORG-100040903

Address

Ul. Grabiszynska 105, 53-439, Poland

Departments

#048003: Poradnia Leczenia Nowotworów Piersi
#8005; Oddzial Hematologiczny
161605: Oddział Hematologiczny
5707:Specjalistyczna Przychodnia Onkologiczna, Poradnia Chemioterapii, Leczenia Nowotworw Piersi
Breast Unit
Centrum Hematologiczno - Transplantacyjne
Centrum Hematologiczno-Transplantacyjne
Clinical Trials Unit
Department of Clinical Oncology
Department of Oncology and Oncological Gynecology
III Klinika Radioterapii i Chemioterapii
Klinika Onkologii
n/a
NA
Oddzial Chirurgii Onkologicznej II - Urologia
Oddzial Hematologiczny
Oddzial Onkologii Klinicznej
Oddzial Onkologii Klinicznej / Chemioterapii Leczenie Skojarzone – Chemioterapia Dzienna
Oddzial Onkologii Klinicznej/Chemioterapii
Oddzial Onkologii/Chemioterapii
Oddzial PL011: Onkologii Klinicznej/Chemioterapii
Oddział Chirurgii Onkologicznej II
Oddział Chemioterapii Dziennej
Oddział Chirurgii II – Pododdział Urologii
Oddział Chirurgii Nowotworów Przewodu Pokarmowego
Oddział Chirurgii Onkologicznej I
Oddział Chirurgii Onkologicznej II- Urologia
Oddział chirurgii onkologicznej II, Pododdział Urologii
Oddział Chirurgii Piersi
Oddział dzienny Onkologii Klinicznej – Breast Unit
Oddział Ginekologii Onkologicznej
Oddział Hematologiczny
Oddział Hematologiczny, Transplantologiczny oraz Immunologii Klinicznej
Oddział Nowotworów Tkanek Miękkich, Skóry i Czerniaków
Oddział Onkologii Klinicznej
Oddział Onkologii Klinicznej (Chemioterapii)
Oddział Onkologii Klinicznej (Nowotworów Klatki Piersiowej)
Oddział Onkologii Klinicznej / Chemioterapii
Oddział Onkologii Klinicznej /Chemioterapii
Oddział Onkologii Klinicznej i Chemioterapii
Oddział Onkologii Klinicznej VII
Oddział Onkologii Klinicznej/ Chemioterapi
Oddział Onkologii Klinicznej/Chemioterapii
Oddział Onkologii/ Chemioterapii
Oddział Onologii Klinicznej
Oddział Urologii
Oddział Urologii Onkologicznej
Odział Onkologii Klinicznej
oncology
Osrodek Badan Klinicznych Wczesnych Faz
Pododdzial Chirurgii II -Urologia
Pododdzial Urologii
Pododział Urologii
Poradnia Chemioterapii
Poradnia Chemioterapii - Leczenie Nowotworów Piers
Poradnia Urologiczna i Oddział Dzienny Onkologii Klinicznej/ Chemioterapii
Urology
Zaklad Radioterapii

Clinical trials at this site (81)

Search interface

Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Locally Advanced or Metastatic Non-small Cell Lung Canc 5 2025-06-12
A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting

2023-506327-29-00 Non-Small Cell Lung Cancer 5 2025-05-14
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adult Patients Wi… Recruiting

2024-515593-27-00 relapsed or refractory mantle cell lymphoma (R/R MCL) 5 2025-05-08
A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-514281-39-00 Metastatic Squamous Non-small Cell Lung Cancer Whose Tu 5 2025-02-14
A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-515008-38-00 Metastatic Non-squamous Non-small Cell Lung Cancer Whos 5 2025-02-14
A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt… Recruiting

2023-507684-19-00 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Can 5 2024-07-24
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo… Recruiting

2023-506308-24-00 Recurrent or metastatic head and neck squamous cell car 10 2024-05-22
CardioPROTECTion With Dapagliflozin in Breast Cancer Patients Treated With AnthrAcycline - PROTECTAA TRIAL Recruiting

2023-506631-15-00 Patients with invasive breast cancer, on stage I-III, a 5 2024-04-15
A trial to learn if volrustomig is safe and efficacious in women and young adults with locally advanced cervical cancer. Recruiting

2023-504374-38-00 Locally advanced cervical cancer 5 2024-04-12
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RV… Recruiting

2023-505911-19-00 Acute Myeloid Leukemia 4 2024-01-05
An international randomised trial of radical surgery followed by adjuvant therapy versus no further treatment in patients with early-stage, … Recruiting

2023-504973-19-01 early-stage, intermediate-risk cervical cancer 5 2023-09-06
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics… Recruiting

2023-510061-10-00 Clear cell renal cell carcinoma (ccRCC, first-, second- 3 2023-01-09
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or… Recruiting

2023-507149-27-00 Chemotherapy-induced Thrombocytopenia in Adult subjects 5 2019-11-04
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended

2024-513968-25-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-04-28
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother… Ended

2024-511957-23-00 Recurrent or Persistent Endometrial Cancer 5 2025-01-03
Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Extensive stage small cell lung cancer (ES-SCLC) 5 2024-11-21
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive… Ended

2024-510908-37-00 KRAS G12C-Positive Advanced or Metastatic Non-Small Cel 5 2024-08-28
A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapse… Ended

2023-508426-10-00 Relapsed/Refractory Multiple Myeloma 3 2024-06-03
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intraves… Ended

2023-507685-10-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2024-05-30
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15